Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that Kyle Kuvalanka, chief business officer, will present a company overview at the JMP Securities Life Sciences...
-
CAMBRIDGE, Mass., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that Kyle Kuvalanka, chief business officer, will present a company overview at the 13th Annual BIO Investor...
-
CAMBRIDGE, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that members of the Company's senior management team will participate in the Morgan Stanley Global Healthcare...
-
CAMBRIDGE, Mass., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that members of the Company's senior management team will present at the Wedbush 2014 Life Sciences Management...
-
CAMBRIDGE, Mass., June 20, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that Kyle Kuvalanka, chief business officer, will present a company overview at the JMP Securities Healthcare...
-
CAMBRIDGE, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that promising preclinical data on its first-in-class selective fibroblast growth factor receptor 4 (FGFR4)...
-
CAMBRIDGE, Mass., March 24, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that new data on its first-in-class isoform selective fibroblast growth factor receptor 4 (FGFR4) inhibitor...
-
CAMBRIDGE, Mass, March 20, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that members of the Company's senior management team will present at upcoming financial...